Separation Date; Transition Period and Services. Employee acknowledges that the last date of Employee’s employment relationship with or service to the Company or any of its Affiliates in any capacity is March 31, 2023 (the “Separation Date”). Between now and the Separation Date (the “Transition Period”), Employee agrees to carry out the duties and responsibilities of Employee’s position as directed principally by the Company’s Board of Directors (the “Board”), to whom Employee will continue to report, and to provide other transition services as may reasonably be requested by the Company, including transition of the responsibilities, duties, and knowledge relative to Employee’s position (the “Transition Services”).
Separation Date; Transition Period and Services. Your last day of employment with the Company will be August 16, 2023 (the “Separation Date”). Between now and the Separation Date (the “Transition Period”), you agree to carry out the duties and responsibilities of your position as directed principally by the Company’s executive leadership, including its interim CFO, and to provide other transition services as may reasonably be requested by the Company, including, without limitation, (i) transition of the responsibilities, duties, and knowledge relative to your position, and (ii) if requested by the Company, execution of the Company’s August 2023 10-Q financial statement, providing you shall not be required to sign the 2023 10-Q unless you believe the 10-Q and the required attestations are accurate (the “Transition Services”). During the Transition Period, you will primarily work remotely and come into the Company’s San Jose, California headquarters only when and as requested by the new interim CFO. By signing below, you hereby resign, effective as of the Separation Date, from all officer positions of the Company that you may hold, including, without limitation, the position of Acting Chief Financial Officer of the Company.
Separation Date; Transition Period and Services. Your last day in your current role of President and Chief Revenue Officer will be December 31, 2020, and your last day of employment with the Company will be February 12, 2021 (the “Separation Date”) subject to the at-will nature of your employment, as described in Paragraph 2(d) below. Between now and the Separation Date (the “Transition Period”), you agree to carry out such transition services as directed principally by the Company’s Chief Executive Officer, Xxxx Xxxxxxxx, to whom you will report, including transition of the responsibilities, duties, and knowledge relative to your position (the “Transition Services”).
Separation Date; Transition Period and Services. If you enter into this Agreement, and it becomes effective, January 4, 2016 will be your last day of employment with the Company (the “Separation Date”).
Separation Date; Transition Period and Services. Your last day of employment with the Company will be March 16, 2022 (the “Separation Date”) subject to the at-will nature of your employment, as described in Paragraph 2(d) below. Between now and the Separation Date (the “Transition Period”), you agree to carry out such transition services as directed principally by the Company’s Chief Executive Officer, Xxxx Xxxxxxxx, to whom you will report, including transition of the responsibilities, duties, and knowledge relative to your position (the “Transition Services”).
Separation Date; Transition Period and Services. Your last day of employment with the Company will be May 10, 2022 (the “Separation Date”), subject to Section 2(d), below. Between the Effective Date (as defined below) and the Separation Date (such period the “Transition Period”), you shall continue to be employed by the Company as follows: (i) on the Effective Date, you will transition into a Transitioning CFO role and will serve in that capacity until the Separation Date; (ii) while you are serving as a Transitioning CFO during the Transition Period, you agree to provide the following services upon written request by the SVP of People of the Company: support the Company during its first quarter 2022 earnings call (Section 2(a)(ii) collectively referred to as the “Transition Services”); (iii) on the Separation Date at the close of business, your employment with the Company will cease; and (iv) from the Separation Date until August 5, 2022, subject to earlier termination for any reason by either you or the Company upon seven (7) days prior written notice (the “Advisory Period”), you agree to be available upon written request by the SVP of People to provide advisory services to the Company to support an orderly transition of your duties (the “Advisory Services”). From the Effective Date until the Separation Date, you will be able to access your email address, your computer, and your home office equipment solely to perform the Transition Services as requested by the Company’s SVP of People. During the Transition Period and the Advisory Period, you agree direct all communications to the Company’s employees and Board members regarding the Company’s business through the Company’s SVP of People. You will remain covered by the Company’s existing Director & Officer Liability Insurance policy (the “Existing Policy”) while you remain employed by the Company, and thereafter, so long as the Existing Policy is in effect, which Existing Policy covers former officers and is a “claims made” policy.
Separation Date; Transition Period and Services. Your last day of employment with the Company will be the earliest of (i) the date upon which a new Chief Financial Officer or other principal financial officer commences employment with the Company, (ii) the date that Aisling Capital LLC (“Aisling”) completes fundraising for its fourth fund, (iii) the date upon which you or the Company terminate your employment pursuant to Paragraph 2(c) below, or (iv) September 1, 2015 (the “Separation Date”). Between now and the Separation Date (the “Transition Period”), you agree to carry out the duties and responsibilities of your position (including, but not limited to, managing the internal finance function of the Company and preparing, signing, and filing any Securities and Exchange Act filings required to be signed by the Company’s principal financial officer), as directed principally by the Chief Executive Officer, to whom you will report, and to provide other transition services as may reasonably be requested by the Company, including transition of the responsibilities, duties, and knowledge relative to your position (the “Transition Services”). During the Transition Period, you will maintain a part-time schedule. Effective on the first day of the Transition Period, your title will change from Chief Financial Officer to Acting Chief Financial Officer.
Separation Date; Transition Period and Services. Your last day of employment with the Company will be March 31, 2024 (the “Anticipated Separation Date”), subject to the at-will nature of your employment as described in Section 2(d), below. Between now and the Anticipated Separation Date (the “Transition Period”), you agree to carry out the duties and responsibilities of your position, including those related to the consummation of the Company’s transaction with FICV, and to provide other transition services as may reasonably be requested by the Company, including transition of the responsibilities, duties, and knowledge relative to your position (the “Transition Services”). During the Transition Period, you will maintain a full-time schedule.
Separation Date; Transition Period and Services. Your last day of employment with the Company will be the earliest of (i) the date upon which you or the Company terminate your employment pursuant to Paragraph 2(c) below, or (ii) December 31, 2015 (the “Separation Date”). Between now and the Separation Date (the “Transition Period”), you agree to carry out the duties and responsibilities of the Acting Chief Medical Officer position (including, but not limited to providing back-up advice regarding clinical trial, operational and safety issues; providing limited regulatory advice; representing the Company as a clinical development consultant or acting Chief Medical Officer (“CMO”)at global regulatory meetings; providing CMO signature for SOPS, internal documentation of medical approval, letters to investigators and health authorities regarding safety related issues; consulting with Company staff on compassionate use requests; acting Principal Investigator certain applications and activities) as directed principally by the Chief Executive Officer, to whom you will report; and providing other transition services as may reasonably be requested by the Company, including transition of the responsibilities, duties, and knowledge relative to your position to other employees of the Company (the “Transition Services”). You will maintain a full-time schedule until November 12, 2015. Thereafter during the Transition Period, you will maintain a part-time schedule based on an approximate average of 8 hours/week. Effective on the first day of the Transition Period, your title will change from Chief Medical Officer to Acting Chief Medical Officer, and you will no longer hold the title of Executive Vice President, Research and Development.
Separation Date; Transition Period and Services. Executive’s last day of employment with the Company will be December 31, 2022 (the “Termination Date”) subject to the at-will nature of Executive’s employment, as described in Section 2(d) below. Between now and the Termination Date (the “Transition Period”), Executive agrees to carry out such transition services as directed principally by the Company’s Chief Executive Officer, to whom Executive will report, including transition of the responsibilities, duties, and knowledge relative to Executive’s position (the “Transition Services”).
